Display options
Cite
Geoffroy MC, Esnault C, de Thé H. Retinoids in hematology: a timely revival?. Blood. 2021;137(18):2429-2437doi: 10.1182/blood.2020010100.
Geoffroy, M. C., Esnault, C., & de Thé, H. (2021). Retinoids in hematology: a timely revival?. Blood, 137(18), 2429-2437. https://doi.org/10.1182/blood.2020010100
Geoffroy, Marie-Claude, et al. "Retinoids in hematology: a timely revival?." Blood vol. 137,18 (2021): 2429-2437. doi: https://doi.org/10.1182/blood.2020010100
Geoffroy MC, Esnault C, de Thé H. Retinoids in hematology: a timely revival?. Blood. 2021 May 06;137(18):2429-2437. doi: 10.1182/blood.2020010100. PMID: 33651885.
Copy Download .nbib Format: NLM
Share it on

Blood. 2021 May 06;137(18):2429-2437. doi: 10.1182/blood.2020010100.

Retinoids in hematology: a timely revival?.

Blood

Marie-Claude Geoffroy, Cécile Esnault, Hugues de Thé

Affiliations

  1. INSERM Unité (U)944, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 7212, Institut de Recherche Saint-Louis (IRSL), Université de Paris, Hôpital Saint-Louis, Paris, France.
  2. Collège de France, Paris Sciences et Lettres (PSL) Research University, INSERM U1050, CNRS, UMR 7241, Paris, France; and.
  3. Service de Biochimie, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.

PMID: 33651885 DOI: 10.1182/blood.2020010100

Abstract

The retinoic acid receptors (RARA, RARB, and RARG) are ligand-regulated nuclear receptors that act as transcriptional switches. These master genes drew significant interest in the 1990s because of their key roles in embryogenesis and involvement in a rare malignancy, acute promyelocytic leukemia (APL), in which the RARA (and very rarely, RARG or RARB) genes are rearranged, underscoring the central role of deregulated retinoid signaling in leukemogenesis. Several recent provocative observations have revived interest in the roles of retinoids in non-APL acute myeloid leukemia (AML), as well as in normal hematopoietic differentiation. We review the role of retinoids in hematopoiesis, as well as in the treatment of non-APL AMLs. From this perspective, broader uses of retinoids in the management of hematopoietic tumors are discussed.

© 2021 by The American Society of Hematology.

Publication Types